Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Safety

FDA Faults China’s Hisun Pharmaceutical

by Jean-François Tremblay
January 25, 2016 | A version of this story appeared in Volume 94, Issue 4

FDA has released a warning letter it issued to Zhejiang Hisun Pharmaceutical, a major Chinese drug supplier. In September, FDA had banned from the U.S. most active pharmaceutical ingredients made at Hisun’s Taizhou facility. In the letter, FDA details numerous instances of data manipulation and deletions. “Our investigators found that your firm routinely re-tested samples without justification and deleted analytical data,” the letter says. Hisun staff also impeded FDA officials’ work, according to the letter. For instance, a Hisun employee took off with a thumb drive when an inspector ordered him to hand it over during an inspection in March. FDA notes that its “concerns about deletion of data are heightened by the significant number of customer complaints for subpotency and out-of-specification impurity levels from 2012 to 2014.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.